April 18, 2024

Norwegian startup ClexBio is bioengineering human veins to implant inside a affected person’s physique.

Along with CSEM, a Swiss R&D centre, the corporate has constructed a prototype bioreactor to develop the veins.

Pre-clinical exams in animal fashions are already underway. Primarily based on the early outcomes, the workforce is assured that the implants don’t set off an immune response in sufferers. As a substitute, they flip into practical tissue that integrates with the physique.

If additional exams show profitable, the implants might deal with extreme continual venous insufficiency, a painful situation precipitated when veins have issues transferring blood to the center.

However veins are simply the beginning of the corporate’s ambitions. ClexBio envisions bioengineering producing varied medical remedies.

“Sooner or later, we consider tissue therapeutic options will present a treatment for lots of the continual situations which are debilitating for our society at present,” Armend Håti, the startup’s CEO and co-founder, informed TNW.

Bioengineering physique elements

A series of bioreactors for bioengineering vein grafts, developed by CSEM and ClexBio